Mr. Ronald Li reports
NOVOHEART TO DEBUT NEW, STATE-OF-THE-ART HUMAN HEART-IN-A-JAR 2.0 TECHNOLOGY AT THE 2018 INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH (ISSCR) ANNUAL MEETING
The next generation of Novoheart Holdings Inc.'s human-heart-in-a-jar technology -- which makes up a key component of its comprehensive MyHeart platform -- will be unveiled for the first time at the Annual Meeting of the International Society for Stem Cell Research (ISSCR), held in Melbourne, Australia, from June 20 to June 23, 2018. The annual meeting is the flagship event of the professional society where cutting-edge stem cell research will be presented to over 4,000 attendees, which include notable scientists, innovators, industry representatives and media. Building on the world's first and only human heart in a jar (otherwise known as the human ventricular cardiac organoid chamber (or hvCOC)), developed by and exclusively available through Novoheart, the company's proprietary human-heart-in-a-jar 2.0 technology boasts substantially enhanced throughput, efficiency, sensitivity and accuracy for advanced drug discovery.
The first-generation, fluid-ejecting, three-dimensional human heart in a jar is the only technology on the market to date that enables the clinically informative assessment of human cardiac pump performance (such as cardiac output and ejection fraction), which no other engineered heart tissues on the market are capable of. Dr. Kevin Costa, chief scientific officer of Novoheart, will present to the attendees of the ISSCR annual meeting the new human heart in a jar 2.0, demonstrating its ability to deliver an over-200-fold increase in efficiency, throughput, sensitivity and accuracy, compared with the first generation. This marked enhancement is achieved through a combination of custom-designed hardware and software developed to complement the best-in-class hvCOC biological construct.
With a new bioreactor design that allows precise temperature and environmental control as well as simultaneous, 24-hour-a-day/seven-day-a-week monitoring of multiple heart-in-a-jar constructs, intermittent or infrequent, potentially fatal adverse side effects of drug compounds can be captured. Semi-automation of the testing procedures with real-time visualization of data readouts streamlines the measurement process and greatly reduces manpower requirement. Software developments enhance signal processing and enable efficient extraction of key parameters from the acquired data that can be immediately integrated with Novoheart's established artificial intelligence technology, allowing the detection of drug toxicity and efficacy to the human heart in an unprecedented manner. In addition to modelling healthy human heart function, the versatility of the human heart in a jar has also been proved in effective disease models using patient-derived induced pluripotent stem cells, presenting virtually unlimited choices for Novoheart's clients that cannot be offered by animal-based testing.
"We are very excited about the second generation of the human-heart-in-a-jar technology that will allow us to further offer our clients industry-leading insight into the toxicity effects of drug candidates," said Dr. Costa. "These latest enhancements further differentiate our MyHeart platform from other competing technologies."
About Novoheart Holdings Inc.
Novoheart is a global stem cell biotechnology company pioneering an array of next-generation human heart tissue prototypes. It is the first company in the world to have engineered miniature living human heart pumps that can revolutionize drug discovery, helping to save time and money for developing new therapeutics.
We seek Safe Harbor.
© 2023 Canjex Publishing Ltd. All rights reserved.